GM2A

ganglioside GM2 activator, the group of MD-2 related lipid recognition domain containing

Basic information

Region (hg38): 5:151212150-151270440

Links

ENSG00000196743NCBI:2760OMIM:613109HGNC:4367Uniprot:P17900AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • Tay-Sachs disease AB variant (Definitive), mode of inheritance: AR
  • Tay-Sachs disease AB variant (Strong), mode of inheritance: AR
  • Tay-Sachs disease AB variant (Strong), mode of inheritance: AR
  • Tay-Sachs disease AB variant (Definitive), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
GM2-gangliosidosis, AB variantARGeneralGenetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testingBiochemical; Neurologic; Ophthalmologic5135907; 10364519; 11339652

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the GM2A gene.

  • Tay-Sachs disease, variant AB (2 variants)
  • Tay-Sachs disease (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the GM2A gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
1
clinvar
23
clinvar
1
clinvar
25
missense
2
clinvar
56
clinvar
3
clinvar
4
clinvar
65
nonsense
1
clinvar
1
start loss
0
frameshift
2
clinvar
2
inframe indel
1
clinvar
1
splice donor/acceptor (+/-2bp)
0
splice region
1
8
2
11
non coding
1
clinvar
45
clinvar
14
clinvar
32
clinvar
92
Total 2 5 102 40 37

Variants in GM2A

This is a list of pathogenic ClinVar variants found in the GM2A region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
5-151223934-G-T not specified Uncertain significance (Apr 20, 2024)3264268
5-151223935-T-G not specified Uncertain significance (Dec 16, 2022)2267427
5-151252773-C-T Benign (Jun 21, 2021)1267493
5-151253113-T-C Tay-Sachs disease, variant AB Uncertain significance (Jan 12, 2018)904951
5-151253115-A-G Tay-Sachs disease, variant AB Benign (Jun 19, 2021)352249
5-151253134-C-G Tay-Sachs disease, variant AB Uncertain significance (Jan 13, 2018)904952
5-151253173-G-A Tay-Sachs disease, variant AB Benign (Jan 12, 2018)352250
5-151253210-C-G Tay-Sachs disease, variant AB Uncertain significance (Jan 13, 2018)352251
5-151253220-C-T Tay-Sachs disease, variant AB Likely pathogenic (Sep 06, 2021)1324484
5-151253221-A-G Tay-Sachs disease, variant AB Uncertain significance (Jul 08, 2022)2170689
5-151253227-T-A Tay-Sachs disease, variant AB Uncertain significance (Mar 11, 2022)836689
5-151253229-A-C Tay-Sachs disease, variant AB Uncertain significance (Jun 21, 2022)1983204
5-151253229-A-T Tay-Sachs disease, variant AB Uncertain significance (Mar 27, 2022)904953
5-151253230-T-C Inborn genetic diseases Uncertain significance (Apr 08, 2023)2561453
5-151253240-C-T Tay-Sachs disease, variant AB Likely benign (Jul 07, 2023)1649650
5-151253249-C-T Tay-Sachs disease, variant AB • GM2A-related condition Benign/Likely benign (Oct 13, 2022)723305
5-151253252-C-T Tay-Sachs disease, variant AB Likely benign (Aug 17, 2023)2037423
5-151253253-C-T Tay-Sachs disease, variant AB Uncertain significance (Jan 12, 2018)904954
5-151253255-G-A Tay-Sachs disease, variant AB Likely benign (Sep 07, 2022)653201
5-151253271-G-A not specified • Tay-Sachs disease, variant AB Benign (Feb 01, 2024)256030
5-151253273-C-G Tay-Sachs disease, variant AB Likely benign (Jun 23, 2023)2817168
5-151253275-C-T Inborn genetic diseases Uncertain significance (Dec 06, 2022)2333442
5-151253294-A-T Tay-Sachs disease, variant AB Likely benign (Jan 19, 2024)352252
5-151253301-A-G Tay-Sachs disease, variant AB Uncertain significance (Jul 26, 2022)2072336
5-151253547-C-A Benign (Jun 20, 2021)1228124

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
GM2Aprotein_codingprotein_codingENST00000357164 458291
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.03100.824125739091257480.0000358
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense-0.2981161071.080.000005931252
Missense in Polyphen3234.370.93104436
Synonymous-1.105444.61.210.00000255399
Loss of Function1.1436.010.4992.53e-776

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.00008670.0000867
Ashkenazi Jewish0.000.00
East Asian0.000.00
Finnish0.000.00
European (Non-Finnish)0.00004400.0000439
Middle Eastern0.000.00
South Asian0.00003270.0000327
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: The large binding pocket can accommodate several single chain phospholipids and fatty acids, GM2A also exhibits some calcium-independent phospholipase activity (By similarity). Binds gangliosides and stimulates ganglioside GM2 degradation. It stimulates only the breakdown of ganglioside GM2 and glycolipid GA2 by beta-hexosaminidase A. It extracts single GM2 molecules from membranes and presents them in soluble form to beta- hexosaminidase A for cleavage of N-acetyl-D-galactosamine and conversion to GM3. {ECO:0000250}.;
Disease
DISEASE: GM2-gangliosidosis AB (GM2GAB) [MIM:272750]: An autosomal recessive lysosomal storage disease marked by the accumulation of GM2 gangliosides in the neuronal cells. It is characterized by GM2 gangliosides accumulation in the presence of both normal hexosaminidase A and B. {ECO:0000269|PubMed:1915858, ECO:0000269|PubMed:8244332, ECO:0000269|PubMed:8900233}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Lysosome - Homo sapiens (human);Degradation pathway of sphingolipids, including diseases;Neutrophil degranulation;Metabolism of lipids;Innate Immune System;Immune System;Metabolism;Glycosphingolipid metabolism;Sphingolipid metabolism (Consensus)

Recessive Scores

pRec
0.194

Intolerance Scores

loftool
0.376
rvis_EVS
0.68
rvis_percentile_EVS
84.93

Haploinsufficiency Scores

pHI
0.267
hipred
N
hipred_score
0.146
ghis
0.404

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.601

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Gm2a
Phenotype
nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan);

Gene ontology

Biological process
glycosphingolipid metabolic process;ganglioside catabolic process;lipid transport;learning or memory;oligosaccharide catabolic process;lipid storage;neutrophil degranulation;neuromuscular process controlling balance;positive regulation of hydrolase activity
Cellular component
extracellular region;cytoplasmic side of plasma membrane;basolateral plasma membrane;apical plasma membrane;azurophil granule lumen;lysosomal lumen;extracellular exosome
Molecular function
lipid transporter activity;phospholipase activator activity;sphingolipid activator protein activity;beta-N-acetylgalactosaminidase activity